<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The receptor for <z:chebi fb="1" ids="16336">hyaluronic acid</z:chebi>-mediated motility (RHAMM) is an antigen eliciting both humoral and cellular immune responses in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="1" pm="."><plain>We initiated a phase 1 clinical trial vaccinating 10 patients with R3 (ILSLELMKL), a highly immunogenic CD8(+) T-cell <z:chebi fb="0" ids="53000">epitope</z:chebi> <z:chebi fb="7" ids="16670">peptide</z:chebi> derived from RHAMM </plain></SENT>
<SENT sid="2" pm="."><plain>In 7 of 10 patients, we detected an increase of CD8(+)/HLA-A2/RHAMM R3 tetramer(+)/CD45RA(+)/CCR7(-)/CD27(-)/CD28(-) effector T cells in accordance with an increase of R3-specific CD8(+) T cells in enzyme linked immunospot (ELISpot) assays </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:chebi fb="74" ids="28073">chromium</z:chebi> release assays, a specific lysis of RHAMM-positive leukemic blasts was shown </plain></SENT>
<SENT sid="4" pm="."><plain>Three of 6 patients with myeloid disorders (1/3 AML, 2/3 MDS) achieved clinical responses: one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and one with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> showed a significant reduction of blasts in the bone marrow after the last vaccination </plain></SENT>
<SENT sid="5" pm="."><plain>One patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> no longer needed erythrocyte transfusions after 4 vaccinations </plain></SENT>
<SENT sid="6" pm="."><plain>Two of 4 patients with MM showed a reduction of free light chain serum levels </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together, RHAMM-R3 <z:chebi fb="7" ids="16670">peptide</z:chebi> vaccination induced both immunologic and clinical responses, and therefore RHAMM constitutes a promising target for further immunotherapeutic approaches </plain></SENT>
<SENT sid="8" pm="."><plain>This study is registered at http://ISRCTN.org as ISRCTN32763606 and is registered with EudraCT as 2005-001706-37 </plain></SENT>
</text></document>